Overview

This trial is active, not recruiting.

Condition epilepsy
Treatment esl
Sponsor Bial - Portela C S.A.
Start date February 2012
End date December 2016
Trial size 300 participants
Trial identifier NCT01532726, BIA-2093-403

Summary

This is a multicenter, non-interventional, prospective study. The observation period comprises at least 6 months, from the initiation of ESL add-on therapy in adult patients with partial-onset epilepsy not sufficiently controlled with one AED, until the first visit that occurs between 6 and 9 months of follow-up. The observation period will end after 9 months of follow-up even if the final assessment is not performed.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective
Arm
ESL and concomitant medication should be managed by the neurologist according to the respective SPC.Summary of Product Characteristics
esl Zebinix
ESL 400/800/1200 mg tablets once daily

Primary Outcomes

Measure
ESL retention rate
time frame: 9 months

Secondary Outcomes

Measure
CGI-C score at the final assessment.
time frame: 9 monthss
Changes in CGI-S score from baseline to final assessment
time frame: 9 months
CGI-Efficacy Index scores at the final assessment
time frame: 9 months
Proportion of patients who are responders to ESL (at least 50% reduction in seizure frequency) at the final assessment
time frame: 9 months
Proportion of seizure-free patients within the 12 weeks prior to final assessment
time frame: 9 months
Proportion of seizure-free patients within the 4 weeks prior to final assessment
time frame: 9 months
Changes in seizure frequency for partial seizures with or without secondary generalization, from baseline to final assessment
time frame: 9 months
Changes in seizure frequency for partial seizures without secondary generalization, from baseline to final assessment
time frame: 9 months
Changes in seizure frequency for partial seizures with secondary generalization, from baseline to final assessment
time frame: 9 months
Changes in QOLIE-10-P scores from baseline to final assessment
time frame: 9 months
Occurrence of AEs during the study (overall and treatment-related)
time frame: 9 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Male or female outpatient, 18 years or older; - The patient has an established diagnosis of epilepsy and has experienced at least one partial-onset seizure, with or without secondary generalization, within four weeks prior to initiation of adjunctive ESL; - The patient is not sufficiently controlled on a current antiepileptic monotherapy and, in the neurologist clinical judgment, it is in the patient's best interest to be prescribed with adjunctive ESL; - The neurologist's decision to prescribe ESL has been made before and independently of his/her decision to include the patient in this study; - The patient's treatment is in accordance with the SPC of ESL; - Written informed consent from the patient (or legally acceptable representative, if the subject is unable to provide informed consent). Exclusion Criteria: - Known hypersensitivity to the active substance, carboxamide derivatives (e.g. oxcarbazepine or carbamazepine) or to any of its excipients; - Patient with 2nd or 3rd degree atrioventricular block; - Patient treated with an experimental drug within four weeks prior to the introduction of ESL; - Female patient who is pregnant, lactating, or who is planning to become pregnant during the study period; - Patient starting ESL outside the approved SPC at enrolment.

Additional Information

Official title A Non-Interventional, Prospective Study to Assess Seizure Control and Tolerability of Eslicarbazepine Acetate as Adjunctive Therapy to One Baseline Antiepileptic Drug, in Adults With Partial-Onset Seizures With or Without Secondary Generalization
Principal investigator João Chaves, MD
Description To ensure non-interventional status, the neurologist's decision that it is in the patient's best interest to be prescribed with adjunctive ESL has to be made before and independently of his/her decision to include the patient in the study. At all circumstances during the study the patients will be treated and followed according to routine clinical practice. ESL and concomitant medication should be managed by the neurologist according to the respective Summary of Product Characteristics (SPC).In order to reflect real-life practice and to ensure the observational nature of this study, no fixed time-points for study assessment were defined. Intermediate follow-up data will be collected whenever a patient attends to the study's neurologist consultation.
Trial information was received from ClinicalTrials.gov and was last updated in January 2016.
Information provided to ClinicalTrials.gov by Bial - Portela C S.A..